Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2–5

Summary

We previously demonstrated a significant margin of haemostatic safety for full-length plasmin in comparison with tissue plasminogen activator (t-PA). We now report studies that compare haemostatic safety of full-length plasmin with a novel recombinant plasmin derivative, (Δ K2–5) plasmin, consisting of kringle 1 linked to the serine protease domain of plasmin. Agent was administered intravenously in a randomised, blinded manner in a rabbit model of fibrinolytic haemorrhage. A dose-related decrease in α₂-antiplasmin, factor VIII, and fibrinogen followed administration of 1.8, 2.7, 3.7 and 4.6 mg/kg of (Δ K2–5) plasmin, with nadir fibrinogen concentrations of 65%, 40%, 30%, and 0% of initial levels, respectively. Mean primary bleeding time was undisturbed at 1.8 mg/kg (2.2 ± 0.7 minutes), minimally prolonged at 2.7 or 3.7 mg/kg (5 ± 2.9 and 4.4 ± 2.2 minutes), and prolonged at the purposefully toxic 4.6 mg/kg dose (12.8 ± 18.8 minutes). Equimolar amounts of (Δ K2–5) plasmin and full-length plasmin had equal in vitro clot lysis efficacy, but in the bleeding model, (Δ K2–5) plasmin showed better haemostatic competency than full-length plasmin. This safety advantage may be explained by higher residual amounts of plasma fibrinogen in animals given (Δ K2–5) plasmin rather than full-length plasmin. We demonstrate that a unique recombinant plasmin mutant, (Δ K2–5) plasmin, possesses an advantage in hemostatic safety over an equimolar amount of full-length plasmin.

Keywords

Plasmin - recombinant derivative - haemostasis

• References

• 1 Ambrus JL, Ambrus CM, Sokal JE. et al. Clinical pharmacology of various types of fibrinolytic enzyme preparations. In: Symposium on Fibrinolysis. Amer J Cardiol 1960; 6: 462-475.
• 2 Alkjaersig N, Fletcher AP, Sherry S. The mechanism of clot dissolution by plasmin. J Clin Invest 1959; 38: 1086-1095.
• 3 Marder VJ. The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med 1979; 90: 802808.
• 4 Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93: 647-654.
• 5 Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
• 6 Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost 2003; 1: 1034-1041.
• 7 Shlansky-Goldberg RD, Matsumoto AH, Baumbach GA. et al. A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. J Thromb Haemost 2008; 6: 944-950.
• 8 Marder VJ, Landskroner K, Novokhatny V. et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-745.
• 9 Stewart D, Kong M, Novokhatny V. et al. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 2003; 101: 3002-3007.
• 10 Comerota AJ. Development of catheter-directed intrathrombus thrombolysis for treatment of peripheral arterial occlusion. Thromb Res 2008; 122 (Suppl. 03) S20-S26.
• 11 NCT01014975: A safety and dose finding study of plasmin (human administered into the middle cerebral artery of stroke patients. ClinicalTrials.gov, updated March 29, 2010 by Talecris Biotherapeutics.
• 12 Sottrup-Jensen L, Clayes H, Zajdel M. et al. The primary structure of human plasminogen. Isolation of two lysine-binding fragments and one ‘Mini-‘plasminogen (MW 38,000) by elastase-catalyzed-specific limited proteolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis. New York: Raven Press; 1978. pp. 191-209.
• 13 Shi GY, Wu HL. Isolation and characterization of microplasminogen. A low molecular weight form of plasminogen. J Biol Chem 1988; 263: 17071-17075.
• 14 Medynski D, Tuan M, Liu W. et al. Refolding, purification and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies. Protein Expr Purif 2007; 52: 395-402.
• 15 Nagai N, Demarsin E, Van Hoef B. et al. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost 2003; 1: 307-313.
• 16 Castellino FJ, McCance SG. The kringle domains of human plasminogen. CIBA Found Symp 1997; 212: 46-60.
• 17 Hunt J, Petteway S, Scuderi P. et al. Simplified recombinant plasmin: Production and functional comparison of a novel thromobolytic molecule with plasma-derived plasmin. Thromb Haemost 2008; 100: 413-419.
• 18 Wu TP, Padmanabhan KP, Tulinsky A. The structure of recombinant plasminogen kringle 1 and the fibrin binding site. Blood Coagul Fibrinolysis 1994; 5: 157-166.
• 19 Wiman B, Lijnen HR, Collen D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha 2-antiplasmin and in fibrinogen. Biochim Biophys Acta 1979; 579: 142-154.
• 20 Marder VJ, Shortell CK, Fitzpatrick PG. et al. An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. Thromb Res 1992; 67: 31-40.
• 21 Robbins KC, Summaria L, Hsieh B. et al. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242: 2333-2342.
• 22 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-219.
• 23 Ellis BC, Stransky A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 1961; 58: 477-488.
• 24 Friberger P, Knos M, Gustavsson S. et al. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-145.